Objectif There is growing commercial interest in bio-responsive materials because of their many applications, such as in medicaldiagnostics at the point of care and in drug discovery and development. Our developed assay technologies manipulatethe properties of gold nanoparticles and enzyme-based reactions to detect enzyme activity. Most diagnostics target eitherexpressed antigens (immunodiagnostics) or DNA (molecular diagnostics).Our bio-responsive nanoparticle technology can offer a sensitive, specific and affordable platform for the development of rapidpoint-of-care tests based on simple colour readouts. Additionally one of the great advantages of our technology is the factthat, in addition to diagnosing disease, it can also potentially help in the search for new drugs to treat those diseases. Incontrast to methods that simply measure enzyme concentration, our method actually measures enzyme activity. In this ERCPOC our expected outcomes include a number of important commercial milestones and technical developments to expandthe platform to other diseases and test its application in high throughput drug screening. This valuewill carry through in both licensing and spin-out, since these issues are fundamental to any business venture. Furthermore,we propose a balanced plan that includes technical research combined with commercial investigations and identificationof appropriate industrial partners. At the conclusion of this work, we will be in a much stronger position to immediatelycommercialise this technology, bringing its benefits to the broader healthcare market. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencesgeneticsDNAengineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-OA-2011-PoC - European Research Council ERC Proof of Concept Appel à propositions ERC-2011-PoC Voir d’autres projets de cet appel Régime de financement CSA-SA(POC) - Supporting action (Proof of Concept) Institution d’accueil IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Contribution de l’UE € 147 918,00 Adresse SOUTH KENSINGTON CAMPUS EXHIBITION ROAD SW7 2AZ LONDON Royaume-Uni Voir sur la carte Région London Inner London — West Westminster Type d’activité Higher or Secondary Education Establishments Contact administratif Shaun Power (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Royaume-Uni Contribution de l’UE € 147 918,00 Adresse SOUTH KENSINGTON CAMPUS EXHIBITION ROAD SW7 2AZ LONDON Voir sur la carte Région London Inner London — West Westminster Type d’activité Higher or Secondary Education Establishments Contact administratif Shaun Power (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
